TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00662454
Drug: ethinyl estradiol / levonorgestrel
Normalized name: ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
Study: NCT03084536
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~* Naproxen will be substituted for celecoxib in patients with sulfa allergies.
Study: NCT03084536
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -As per routine care
Study: NCT03084536
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -As per routine care
Study: NCT01856478
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous bolus injection, once weekly
Study: NCT03915964
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00902603
Drug: Commercial Ventavis® (iloprost)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
Study: NCT01721057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03036904
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Study: NCT03036904
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Study: NCT03617510
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
Study: NCT03719820
Drug: aggressive medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
Study: NCT03271528
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
Study: NCT00694707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in capsules.
Study: NCT04081324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01721057
Drug: cDMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional disease-modifying anti-rheumatic drug as a background therapy
Study: NCT02611804
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02611804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01251263
Drug: Estradiol or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
Study: NCT01251263
Drug: Estradiol or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
Study: NCT00121784
Drug: mycophenolate mofetil [CellCept]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1
Study: NCT04082975
Drug: NVP-1203-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose for 7 days
Study: NCT04082975
Drug: NVP-1203 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose for 7 days
Study: NCT04082975
Drug: NVP-1203-R placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose for 7 days
Study: NCT00809809
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo swab
Study: NCT00514774
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 600mg twice daily for study days 0 through 28
Study: NCT03594435
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched to active drug, ibudilast
Study: NCT02082899
Drug: Active Comparator EBI-005 5 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02082899
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00789880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral Vitamin D3 placebo
Study: NCT00445705
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Placebo every 12 hours for 4 weeks
Study: NCT03275792
Drug: D5-0.9%NS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admission for intravascular volume expansion
Study: NCT00285818
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a capsule without a pharmacological active ingredient
Study: NCT02938377
Drug: Recommendation and Counseling for Alcohol Pharmacotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
Study: NCT00445705
Drug: AGN 203818
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: AGN 203818 60 mg every 12 hours for 4 weeks
Study: NCT01177683
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4
Study: NCT01475383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily dosing of placebo capsules following the dosing scheme described in 1.1.
Study: NCT01475383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily dosing of placebo capsules following the dosing scheme described in 1.1
Study: NCT01050491
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, one per day, during one year. Bronchial fibroscopy
Study: NCT04161027
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT02478372
Drug: Local Infiltration Analgesia (LIA)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
Study: NCT00702689
Drug: Gleevec, STI571(Imatinib Mesylate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)
Study: NCT03639883
Drug: AIV001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection
Study: NCT03162783
Drug: ADX-102 Ophthalmic Lipid Solution (0.5%)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
Study: NCT01680185
Drug: Human insulin isophane, Humulin N (Eli Lilly)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all covered above
Study: NCT04124861
Drug: Drug free, IS monotherapy and GC combined with IS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
Study: NCT04352946
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 400mg daily
Study: NCT05271539
Drug: Lucentis alone group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
Study: NCT03383393
Drug: Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intracoronary drugs
Study: NCT03860597
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
Study: NCT00857428
Drug: oxymorphone
Normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT00857428
Drug: Oxymorphone
Normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablets
Study: NCT01710046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
Study: NCT02785172
Drug: IDP-118 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT02785172
Drug: IDP-118 Vehicle Cream
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT02785172
Drug: IDP-118 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT00417118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (capsules)
Study: NCT01389271
Drug: Ventavis inhaled (Iloprost, BAYQ6256)
Normalized name: Ventavis Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
Study: NCT01751893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04330300
Drug: Thiazide or Thiazide-like diuretics
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive (Active Arm)
Study: NCT04330300
Drug: Calcium Channel Blockers
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive (Active Arm)
Study: NCT04330300
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive (Control Arm)
Study: NCT01763190
Drug: SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT01193842
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01193842
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02715401
Drug: HCP1303
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02715401
Drug: HGP1201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02715401
Drug: HIP1402
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02760576
Drug: BAY 987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT03025009
Drug: LY3192767
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT03025009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT02024555
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02024555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
Study: NCT02566304
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02325648
Drug: HIPEC cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
Study: NCT04066179
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 40 mg for initial 7 days
Study: NCT01887223
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
Study: NCT00767325
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
Study: NCT01066481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 6 months
Study: NCT01987804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01161108
Drug: Fast Release Melatonin (FR MLT)
Normalized name: melatonin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
Study: NCT01161108
Drug: Fast Release Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
Study: NCT03930498
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and Gemcitabine
Study: NCT03483038
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
Study: NCT01161108
Drug: Timed Release Melatonin (TR MLT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
Study: NCT01161108
Drug: Timed Release Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
Study: NCT02550756
Drug: CTNX-4975
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00398294
Drug: MK0733, simvastatin / Duration of Treatment: 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03571321
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Remission consolidation regimen:~* 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~* 1000 mg/m2 IV on Day 29
Study: NCT03571321
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken by mouth.~Remission consolidation regimen:~* 60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~* 75 mg/m2 on Days 1-84
Study: NCT03571321
Drug: Methotrexate (Intrathecal Administration)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \[IT\] administration).~Remission consolidation regimen:~* 15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~* 15 mg on Days 1 and 31~Delayed Intensification regimen:~* 15 mg on Days 1, 29, and 36~Maintenance Therapy:~* 15 mg on Day 1~* 15 mg on Day 29 (First 4 courses only)
Study: NCT03571321
Drug: Methotrexate (Intravenous Administration)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interim maintenance regimen:~* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41
Study: NCT03571321
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed Intensification regimen:~* 25 mg/m2 IV on Days 1, 8, 15
Study: NCT03571321
Drug: Methotrexate Oral Product
Normalized name: methotrexate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth.~Maintenance Therapy:~* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\]
Study: NCT06002295
Drug: Methylated Spirit
Normalized name: methylated spirits
Approvals — FDA: no, EMA: no, PMDA: no
Description: After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day.
Study: NCT04634409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT01872897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets as a single dose
Study: NCT00586131
Drug: ammonium chloride or sodium citrate/citric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose dictated by changes in pH
Study: NCT01093742
Drug: HM10560A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administrate at 0 hour on Day 1
Study: NCT01093742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00405977
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
Study: NCT00133718
Drug: Combined lifestyle intervention and optimisation of pharmacological treatment
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. 6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~2. standard care
Study: NCT01773512
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will be using rosuvastatin 40 mg
Study: NCT00598559
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
Study: NCT00434161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing.
Study: NCT00592852
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
Study: NCT04468971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expicient
Study: NCT03267680
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03267680
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00367315
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00543361
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 52 Weeks
Study: NCT00543361
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 52 Weeks
Study: NCT05869097
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Study: NCT02916173
Drug: Recombinant Human Chorionic Gonadotrophin
Normalized name: Recombinant human chorionic gonadotrophin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 unit intramuscular